Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

Completed · Phase 4

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.

Key facts

Study ID

NCT00313391

Run by

Emory University

Starts

2005-12-01

Last updated by the study team

2014-09-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary diagnosis of schizophrenia or schizoaffective disorder
• 4 or more admissions to psychiatric hospital in past year, OR minimum of 2 hospital admissions and at least 2 incarcerations in the previous year
• Medicaid recipient
• Patients requiring concomitant non-antipsychotic psychotropic medication (mood stabilizing, antidepressants, anxiolytics)

You may not qualify if…

• Past or current psychiatric disorder, other than schizophrenia or schizoaffective disorder
• Drug or alcohol dependence
• Serious, unstable medical illness or any acute medical condition
• Pregnant or lactating females
• Prior Risperdal Consta treatment
• Non-English speaking

Where it is running

• Grady Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.